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1  | DIASTOLIC DYSFUNCTION AND 
HEART FAILURE
Ventricular	 stroke	 volume	 is	 influenced	 by	 end-	diastolic	 volume	
through	 the	 Frank-	Starling	 mechanism.	 This	 dictates	 that	 as	 the	




reduce	 end-	diastolic	 volumes	 and	 thereby	 cause	 a	 decrease	 in	
stroke	volume	and	cardiac	output.	This	limits	the	ability	of	the	heart	
to	respond	to	an	increase	in	demand,	which	is	a	definition	of	heart	












tension	 in	volume-	overload	 situations.	Proliferation	of	 collagen	 fi-
bres	(fibrosis)	and	greater	cross-	linking	between	fibres	can	increase	





In	 cardiac	muscle	 there	 are	 four	 isoforms:	 CK-m	 (muscle)	 that	
accounts	 for	 about	70%	of	 total	CK,	of	which	10%-	30%	 is	 bound	
to	the	myofilament	protein	myomesin;	CK-	mt	(mitochondrial)	20%-	
30%	 total;	CK-b	 (brain)	 and	CK-mb	 (muscle/brain)	 are	both	 found	









2  | PULMONARY ARTERY HYPERTENSION 
AND DIASTOLIC DYSFUNCTION






In	 the	study	of	Rain	et	al9	human	PAH	patients	were	 found	 to	
have	 diastolic	 dysfunction.	There	was	 increased	 stiffness	 of	myo-
cardium,	 increased	 collagen	 content	 and	 reduced	phosphorylation	
of	titin	with	no	shift	in	titin	isoforms.	RV	failure	has	also	been	stud-
ied	 in	animal	models	of	PAH.10	 In	 the	monocrotaline	 rat	model	of	





We	have	 used	 the	monocrotaline	 rat	model	 to	 study	 RV	 failure	
in	PAH.	The	end	diastolic	pressure–volume	relationship	(EDPVR)	was	







Intact	 single	myocytes	were	attached	 to	glass	 fibres	and	electri-
cally	stimulated	to	contract	while	being	stretched.	The	end	-	diastolic	
force-	length	 relationship	 (EDFLR)	 was	 recorded	 and	 the	 slope	 was	
found	 to	be	 significantly	 steeper	 in	RV	myocytes	 from	MCT	 rats,	 in	
accord	with	the	steeper	EDPVR	in	vivo.	Furthermore,	it	was	observed	
that	RV	myocytes	 (but	not	 left	ventricular	myocytes)	from	MCT	rats	
had	 significantly	 shorter	 diastolic	 sarcomere	 lengths	 compared	 to	
CON	animals,	 in	 the	absence	of	 changes	 in	either	diastolic	 intracel-






Western	blot	 analysis	 showed	a	 significant	 reduction	 in	protein	
levels	of	CK	in	the	RV	of	MCT	rats.	Furthermore,	when	the	sarcolemma	
was	permeabilised	with	saponin	and	cells	incubated	with	exogenous	
CK	 and	 creatine	 phosphate,	 the	 sarcomere	 length	 of	 RV	myocytes	
from	MCT	rats	significantly	increased.	Conversely	in	CON	myocytes,	








of	heart	 failure.	We	concluded	 that	decreased	CK	expression	 leads	
to	 diastolic	 dysfunction,	 via	 local	 reduction	 in	 ATP:ADP	 ratio	 and	
thus	to	Ca2+-	independent	 force	production	and	diastolic	sarcomere	
shortening.13
3  | BETA- BLOCKER TREATMENT OF PAH
There	is	currently	no	cure	for	PAH	and	novel	treatments	are	needed	
to	 resolve	 this.	The	 importance	of	RV	 function	 in	PAH	patient	 sur-






which	 slow	 the	 cardiac	 remodelling	 caused	 by	 chronic	 sympathetic	





















Experiments	 were	 conducted	 with	 local	 ethical	 approval	 and	
in	 accordance	 with	 UK	 Home	 Office	 and	 European	 Parliament	





istered	 by	 voluntary	 syringe	 feeding.	 Control	 animals	 (CON)	 were	
	injected	with	saline	and	given	sucrose.
As	 we	 were	 specifically	 interested	 in	 the	 cardiac	 effects	 of	
beta-	blocker	 treatment	we	 chose	 to	 use	metoprolol:	 it	 is	 beta-	1	




a	 75	kg	 patient	 (0.17-	2.67	mg/kg	 per	 day).	 Animals	 were	 killed	
when	showing	external	signs	of	heart	failure	(weight	loss,	lethargy,	
laboured	breathing,	piloerection)	(see	Fowler	et	al13).	Data	from	the	
three	 experimental	 groups	 were	 compared	 by	 one-	way	 ANOVA.	
Holm-	Sidak	 (n	numbers	equal)	 or	Tukey	 (n	numbers	uneven)	post 
hoc	 tests	were	 used	 following	 parametric	ANOVA,	 or	Dunn	 post 










eter	 in	 the	RV	during	vena	 cava	 occlusion	 (Figure	1A,	 see	 Fowler	
et al.13	for	details	of	methodology).	The	EDPVR	from	MCT	animals	
was	 significantly	 steeper	 than	 CON,	 indicating	 diastolic	 dysfunc-
tion.	 The	 mean	 value	 for	 MCT+BB	 was	 intermediate	 (Figure	1B)	
representing	 an	 improvement	 in	 diastolic	 function.	 Consistent	
with	 observations	 in	whole	 animals,	 the	 resting	 sarcomere	 length	
of	RV	myocytes	showed	a	progressive	increase	CON	>	MCT+BB	>	
MCT	 (Figure	1C).	BB	 treatment	did	not	affect	diastolic	or	 systolic	







Rats/group 15 13 14
Organ	weights
Body	weight	(g) 301	±	6 257	±	4* 274	±	8*
Heart/body	weight	(mg/g) 3.65	±	0.16 4.82	±	0.23* 5.18	±	0.30*
Lung/body	weight	(mg/g) 4.76	±	0.39 8.74	±	0.46* 9.72	±	0.37*
RV/body	weight	(mg/g) 0.64	±	0.06 1.20	±	0.06* 1.14	±	0.06*
LV+S/body	weight	(mg/g) 2.20	±	0.10 2.55	±	0.13 2.58	±	0.09*
RV:LV+S	ratio 0.30	±	0.04 0.48	±	0.03* 0.45	±	0.02*
Rats/group 9 7 5
In vivo
End	systolic	pressure	(mm	Hg) 39.5	±	2.7 83.2	±	5.2* 101.8	±	9.9*
End	diastolic	pressure	(mm	Hg) 4.6	±	0.7 9.6	±	0.7* 9.9	±	2.3*
Stroke	volume	(μL) 110	±	10 48	±	10* 65	±	5*
ESPVR/Ea 0.93	±	0.27 0.27	±	0.06* 0.57	±	0.20




*P	<	.05,	one-	way	ANOVA.	 Intergroup	differences	between	variables	were	 identified	using	Dunn’s	 (RV:LV+S	and	End	systolic	pressure)	or	Tukey’s	 (all	
others)	post hoc	test.	CON,	control;	MCT,	monocrotaline	treated;	MCT+BB,	monocrotaline	+	beta-blocker	treated;	LV,	left	ventricle;	RV,	right	ventricle;	S,	
septum
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of	 CK-	m	 and	 CK-	mito,	mRNA	 or	 protein	 levels	 between	MCT+BB	









At	 low	 stimulation	 frequency	 (1	Hz)	MCT	myocytes	 had	 greater	
sarcomere	 shortening	 (Figure	3A)	 than	 CON	 and	 MCT+BB,	 which	
we	believe	 is	related	to	the	 longer	action	potential	duration	 in	MCT	
myocytes	promoting	greater	loading	of	Ca2+	stores.22	However,	when	
demand	was	increased	by	increasing	stimulation	frequency,	CON	my-
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